Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
K

Kopran Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Kopran Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹166Cr
+4.6% YoY
+9.7% QoQ
Net profit
₹10Cr
−34.1% YoY
+40.9% QoQ
Margin
11.94%
−2.9 pp YoY
+2.2 pp QoQ
Price₹196
Market cap₹955 Cr
P/E37.1

The short version

Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034. The diagnostics industry Kopran Labs operates in is growing at a CAGR of 14%-15%.

From Kopran Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034.
  • Kopran Labs has shown strong past growth, increasing top line threefold from INR35 crores to INR103 crores in 4 years.
  • The diagnostic segment is expected to participate in this industry growth, with new divisions added recently to drive further revenue.
  • South region operations, started about 3 years ago, hold significant growth potential.
  • Annual addition of 20-25 diagnostic machines is expected, supporting steady volume growth.

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.
  • Annually, they add about 20-25 machines to their reagent rental business.
  • For the current year mentioned, 23-24 machines were added, with a possibility of 1-2 more before year-end.
  • The expected annual investment in machines is around INR 7 to 8 crores.
  • All these capital expenditures are funded through internal accruals, supported by a substantial cash reserve.

2 more points from Kopran Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Kopran Laboratories has close to 120 machines deployed across India on a contracted basis.
  • Each machine is part of a long-term contract averaging around 5 to 5.5 years.
  • The company typically adds 20 to 25 new machines annually; 23-24 machines were added in the current year.
  • These contracts ensure recurrent purchase of consumables, forming an annuity-like revenue stream.
  • Kopran anticipates continuing this orderbook growth annually, funded through internal accruals.
  • They maintain warehousing and cold chain logistics to support ongoing orders.

2 more points from Kopran Ltd's call on order book

Create a free account to keep reading this call

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q3 FY25 results — key figures

Kopran Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue166159+4.6%152+9.7%
Operating profit (EBITDA)2024-15.8%15+34.8%
Operating margin11.94%14.84%-2.9 pp9.72%+2.2 pp
Profit before tax1421-32.4%10+43.6%
Net profit (PAT)1016-34.1%7+40.9%
EPS (₹)2.163.28-34.1%1.53+41.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharmaceuticals (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q3 FY25 results?

Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034. The diagnostics industry Kopran Labs operates in is growing at a CAGR of 14%-15%.

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 37.1 with a market cap of ₹955 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.